The US Senate Judiciary Committee has voted to report critical legislation to make reforms to the nation's dated patent reform system. The 19-member panel voted 15 to four to report the bipartisan Patent Reform Act of 2009 after debating the measure in three executive sessions at the start of the month.
The bill was introduced in early March by Committee Chairman Patrick Leahy (Democrat, Vermont) and former Committee Chairman Orrin Hatch (Republican, Utah). It is the third Congress in which Senators Leahy and Hatch have introduced patent reform legislation. Since 2005, the Senate Judiciary Committee has held eight hearings and several executive meetings to consider the legislation. Members of the Committee have held dozens of meetings with stakeholders and interested parties. In 2007, the Committee reported patent reform legislation, but it stalled on the Senate floor due to a dispute over damages provisions in the bill. The Committee heard from stakeholders about the need for patent reform at a public hearing on March 10.
"Patent reform is an important way that this Committee can contribute to restoring our economic engine and supporting economic recovery," Sen Leahy said, adding that reform is urgently needed as "we need to move forward. Over the last couple of days we have reached agreement on issues that had prevented the bill from moving forward."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze